Corient Private Wealth
ORIC icon

Corient Private Wealth’s Oric Pharmaceuticals ORIC Stock Holding History

Corient Private Wealth’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25,024
Closed -$205K – 2983
2025
Q4 		$205K Buy
+25,024
New +$288K ﹤0.01% 2587

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Corient Private Wealth's ORIC Position: Q1 2026 in Review

Corient Private Wealth sold out of Oric Pharmaceuticals (ORIC) in Q1 2026, closing a stake of 25,024 shares — an estimated $205K sold.

Corient Private Wealth first reported a position in ORIC in Q4 2025 and held it in 1 quarter. The position peaked at $205K in Q4 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • Corient Private Wealth reported no remaining Oric Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Corient Private Wealth sold 25,024 Oric Pharmaceuticals shares in Q1 2026, an estimated $205K.
  • Corient Private Wealth first reported a position in Oric Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Corient Private Wealth's Oric Pharmaceuticals position peaked at $205K in Q4 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on Corient Private Wealth's 13F filing for Q1 2026, filed 15 May 2026.